Skip to content
Contact Us
Collaboration
Patients & Care Partners
Healthcare Providers
Japan
Global
About Us
Who We Are
Company Overview
Our History
Our Leadership
Grant Support
Ethics and Compliance
Our Science
Our Pipeline
Our Disease States of Focus
Expanded Access Policy
Our Medicines
Careers
News
About Us
Who We Are
Company Overview
History
Leadership Team
Grant Support
Ethics and Compliance
Our Science
Our Pipeline
Our Therapeutic Areas of Focus
Expanded Access Policy
Our Medicines
Careers
News
Collaboration
Patients & Care Partners
Healthcare Providers
Japan
Contact Us
News
Press Releases
Current News and Historical Highlights
ALL
ALL
2026
2025
2024
2023
2022
2021
2020
2019
2018
2015
2014
Aug 31, 2026
Veloxis Pharmaceuticals Doses First Patient in RENGEVITY-201 Phase 2 Trial of Pegrizeprument for the Prevention of Organ Rejection in Kidney Transplant Recipients
Jun 17, 2026
Veloxis Pharmaceuticals Showcases Research at the 2026 American Transplant Congress
Apr 22, 2026
Pegrizeprument Granted Orphan Drug Designation for Prevention of Organ Rejection in Heart Transplant Patients
Apr 15, 2026
Aicuris Receives FDA Priority Review for Pritelivir NDA and Presents New Phase 3 Data at ESCMID 2026
Mar 30, 2026
Calliditas Therapeutics AB to Present Exploratory Biomarker and Post-Hoc NefIgArd Analyses at the World Congress of Nephrology
Feb 25, 2026
Asahi Kasei to Acquire Aicuris to Accelerate Growth in Severe Infectious Diseases
Feb 24, 2026
Pritelivir Demonstrates Superior Efficacy in People Living with HIV with Refractory HSV in Phase 3 PRIOH-1
Feb 4, 2026
Aicuris Presents Positive Phase 3 Data for Pritelivir in Immunocompromised Patients with Refractory Herpes Simplex Virus at TANDEM
US-AKTX-2600007 V1.0 6/26